Glutamatergic Modulators: The Future of Treating Mood Disorders?
Authors:
- Carlos ZarateCZCarlos Zarate
- Rodrigo Machado-VieiraRMRodrigo Machado-Vieira
- Ioline HenterIHIoline Henter
- Lobna IbrahimLILobna Ibrahim
- Nancy DiazgranadosNDNancy Diazgranados
- Giacomo SalvadoreGSGiacomo Salvadore
- 1 August 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Harvard Review of Psychiatry
- Vol. 18 (5) , 293-303
Abstract
Mood disorders such as bipolar disorder and major depressive disorder are common, chronic, and recurrent conditions affecting millions of individuals worldwide. Existing antidepressants and mood stabilizers used to treat these disorders are insufficient for many. Patients continue to have low remission rates, delayed onset of action, residual subsyndromal symptoms, and relapses. New therapeutic agents able to exert faster and sustained antidepressant or mood-stabilizing effects are urgently needed to treat these disorders. In this context, the glutamatergic system has been implicated in the pathophysiology of mood disorders in unique clinical and neurobiological ways. In addition to evidence confirming the role of the glutamatergic modulators riluzole and ketamine as proof-of-concept agents in this system, trials with diverse glutamatergic modulators are under way. Overall, this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder.Keywords
This publication has 129 references indexed in Scilit:
- Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to KetamineBiological Psychiatry, 2009
- Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-aspartate AntagonistBiological Psychiatry, 2009
- Glial Loss in the Prefrontal Cortex Is Sufficient to Induce Depressive-like BehaviorsBiological Psychiatry, 2008
- Elevated levels of NR2A and PSD-95 in the lateral amygdala in depressionInternational Journal of Neuropsychopharmacology, 2008
- Targeting the glutamatergic system to develop novel, improved therapeutics for mood disordersNature Reviews Drug Discovery, 2008
- The Role of AMPA receptor modulation in the treatment of neuropsychiatric diseasesExperimental Neurology, 2008
- Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of maniaMolecular Psychiatry, 2008
- Neuroplasticity Mediated by Altered Gene ExpressionNeuropsychopharmacology, 2007
- Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive SymptomsBiological Psychiatry, 2007
- Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorderBrain Research, 2007